Neoborocillin Throat Pain Flurbiprofen Mouthwash 160 ml

Flurbiprofen-based mouthwash.

Therapeutic indications

Neoborocillina Throat Pain Mouthwash is used in the symptomatic treatment of irritative-inflammatory states also associated with oropharyngeal pain (eg gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy.

Dosage and Posology

The drug should be taken according to the following doses and methods: the recommended dose is 2-3 rinses or gargles a day with 10 ml of mouthwash (using the appropriate measuring cup), diluted in half a glass of water or pure.

Overdose

With the use of Neo Borocillin Throat Pain it is rare that overdose situations may occur.

Symptoms of overdose may include nausea, vomiting and gastrointestinal irritation.

Treatment should include gastric lavage and, if necessary, correction of the serum electrolyte picture. There is no specific antidote for flurbiprofen.

Contraindications

• Flurbiprofen is contraindicated in patients with hypersensitivity (asthma, bronchospasm, urticaria or allergic type) to flurbiprofen or to any of the excipients, and to acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs).
• Third trimester of pregnancy.
• Administration of flurbiprofen is not recommended in nursing mothers.
• Do not use in patients who have or have had a peptic ulcer in the past.

Side effects

The use of NEO BOROCILLINA THROAT PAIN, especially if prolonged, can give rise to sensitization or local irritation phenomena; in such cases it is necessary to interrupt the treatment and institute, if necessary, a suitable therapy. The following undesirable effects have been reported, particularly after administration of higher doses systemically:

• Blood and lymphatic system disorders: Thrombocytopenia, aplastic anemia and agranulocytosis.
• Immune system disorders: Anaphylaxis, angioedema, allergic reaction.
• Nervous system disorders: Dizziness, cerebrovascular accidents, visual disturbances, optic neuritis, migraine, paraesthesia, depression, confusion, hallucination, dizziness, discomfort, fatigue and somnolence.
• Ear: and labyrinth disorders Tinnitus.
• Respiratory, thoracic and mediastinal disorders: Reactivity of the respiratory tract (asthma, bronchospasm and dyspnoea).
• Gastrointestinal disorders: The most commonly observed adverse events are gastrointestinal in nature. Nausea, vomiting, diarrhea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, gastrointestinal haemorrhage and exacerbation of colitis and Crohn's disease have been reported following administration of flurbiprofen. Gastritis, peptic ulcer, perforation and ulcer haemorrhage were observed less frequently.
• Skin and subcutaneous tissue disorders: Skin disorders including rash, pruritus, urticaria, purpura and very rarely bullous dermatosis (including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme).
• Renal and urinary disorders: Nephrotoxicity in various forms, including interstitial nephritis and nephrotic syndrome.

As with other NSAIDs, rare cases of renal failure have been reported.

Pregnancy and breastfeeding

During the first and second trimester of pregnancy, flurbiprofen should not be administered except in strictly necessary cases. The drug administered during pregnancy can delay the onset of labor and increase its duration. Administration of flurbiprofen is not recommended in nursing mothers.

Special warnings

At the recommended doses, when using the medicine in its various pharmaceutical forms, any swallowing does not, in itself, cause any harm to the patient, as these doses are much lower than those commonly used in treatments with flurbiprofen by route. systemic.

Neo Borocillina Gola Dolorecollutorio and Neo Borocillina Gola Dolorespray for oral mucosa contain methyl parahydroxybenzoate and propyl parahydroxybenzoate as preservatives: they can cause allergic reactions (even delayed). Due to the presence of sorbitol, patients with rare hereditary problems of fructose intolerance should not take this medicine. The spray contains a small amount of ethyl alcohol less than 100 mg per dose. The mouthwash contains 12.15 vol% ethanol (alcohol), e.g. up to 960 mg per serving, equivalent to approximately 24 ml of beer, 10 ml of wine per serving. It can be harmful to alcoholics. To be taken into consideration in pregnant or lactating women, children and high-risk groups such as people with liver disease or epilepsy. In patients with renal, cardiac or hepatic insufficiency the medicinal product should be used with caution. It is recommended not to combine the medicine with NSAIDs. The use, especially if prolonged, of the product can give rise to sensitization phenomena or local irritation; in such cases it is necessary to interrupt the treatment and consult the doctor to establish, if necessary, a suitable therapy. Do not use for prolonged treatments. After a short period of treatment without appreciable results, consult your doctor.

Expiry and retention

Check the expiration date indicated on the package. The expiry date indicated on the package refers to the product in intact packaging, correctly stored. After first opening the mouthwash is valid for 1 year. No particular storage conditions.

Warning : do not use the medicine after the expiry date indicated on the package.

Composition

100 ml of Neoborocillin Mouthwash contain:

Active principle

Flurbiprofen 0.25 g

Excipients

Glycerol, 96 percent ethanol, non-crystallizable liquid sorbitol, hydrogenated castor oil-40 polyoxyethylenate, sodium hydroxide, sodium saccharin, methyl parahydroxybenzoate, propyl parahydroxybenzoate, essential oil trirectified mint, patent blue V (E 131), anhydrous citric acid, water purified.